CONTINUED EFFICACY AND SAFETY THROUGH 4 YEARS OF TENOFOVIR DISOPROXIL FUMARATE (TDF) TREATMENT IN HBEAG-NEGATIVE PATIENTS WITH CHRONIC HEPATITIS B (STUDY 102): PRELIMINARY ANALYSIS

被引：0

作者：

Marcellin, Patrick ^{[2
]}

Buti, Maria ^{[3
]}

Krastev, Zahary ^{[4
]}

Gurel, Selim ^{[5
]}

Di Bisceglie, Adrian M. ^{[6
]}

Odin, Joseph A. ^{[7
]}

Dusheiko, Geoffrey M. ^{[8
]}

Heathcote, E. Jenny ^{[9
]}

Borroto-Esoda, Katyna ^{[1
]}

Coombs, Derek H. ^{[1
]}

Mondou, Elsa ^{[1
]}

Anderson, Jane ^{[1
]}

机构：

[1] Gilead Sci, Durham, NC USA

[2] Univ Paris, Hop Beaujon, Clichy, France

[3] Univ Vall Hebron & Ciberehd, Serv Med Interna Hepatol, Gen Hosp, Barcelona, Spain

[4] Univ Hosp St Ivan Rilsky, Sofia, Bulgaria

[5] Uludag Univ, Bursa, Turkey

[6] St Louis Univ, Sch Med, St Louis, MO USA

[7] Mt Sinai Sch Med, New York, NY USA

[8] Royal Free Hosp, London NW3 2QG, England

[9] Univ Toronto, Toronto, ON, Canada

来源：

HEPATOLOGY | 2010年 / 52卷 / 04期

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

476

引用

页码：555A / 556A

页数：2

共 50 条

[21] Incidences of Virological and Clinical Relapses After Cessation of Tenofovir Alafenamide, Tenofovir Disoproxil Fumarate, or Entecavir in Patients With HBeAg-Negative Chronic Hepatitis B
Tseng, Cheng-Hao
Lee, Teng-Yu
Chen, Chi-Yi
Huang, Chung-Feng
Chen, Po-Yueh
Jang, Tyng-Yuan
Yang, Tzeng-Huey
Wu, Chia-Ching
Hsu, Yao-Chun
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2025,
[22] A Phase 3 Study Comparing Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide With Continued TDF Treatment in Virologically Suppressed Patients With Chronic Hepatitis B: Week 48 Efficacy and Safety Results
Lampertico, Pietro
Buti, Maria
Fung, Scott
Ahn, Sang Hoon
Chuang, Wan-Long
Tak, Won Young
Ramji, Alnoor
Chen, Chi-Yi
Tam, Edward
Bae, Ho
Ma, Xiaoli
Flaherty, John F.
Gaggar, Anuj
Lau, Audrey
Feierbach, Becket
Wu, George
Suri, Vithika
Subramanian, G. Mani
Oberle, Corinna
Huy Trinh
Yoon, Seung-Kew
Agarwal, Kosh
Lim, Young-Suk
Chan, Henry L. Y.
SWISS MEDICAL WEEKLY, 2019, : 25S - 25S
[23] HBSAG KINETICS IN PATIENTS WITH CHRONIC HEPATITIS B (CHB) TREATED WITH TENOFOVIR DISOPROXIL FUMARATE (TDF) FOR UP TO 4 YEARS
Marcellin, P.
Heathcote, E. J.
Buti, M.
Krastev, Z.
Jacobson, I.
de Man, R. A.
Dusheiko, G.
Zeuzem, S.
Barnes, C.
Ng, C.
Lou, L.
JOURNAL OF HEPATOLOGY, 2011, 54 : S297 - S297
[24] Improved bone and renal safety of switching from tenofovir disoproxil fumarate to tenofovir alafenamide: Preliminary results from two phase 3 studies in HBeAg-positive and HBeAg-negative patients with chronic hepatitis B
Thompson, A.
Gane, E.
Fung, S.
Seto, W. K.
Flaherty, J. F.
Suri, V.
Lin, L.
Gaggar, A.
Subramanian, G. M.
Chuang, W. L.
Agarwal, K.
Janssen, H. L.
Buti, M.
Chan, H. L.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2017, 32 : 109 - 109
[25] TWO YEAR TENOFOVIR DISOPROXIL FUMARATE (TDF) TREATMENT AND ADEFOVIR DIPIVOXIL (ADV) SWITCH DATA IN HBEAG-POSITIVE PATIENTS WITH CHRONIC HEPATITIS B (STUDY 103), PRELIMINARY ANALYSIS
Heathcote, E. Jenny
Gane, Edward J.
deMan, Robert A.
Chan, Sing
Sievert, William
Mauss, Stefan
Marcellin, Patrick
Sorbel, Jeff
Anderson, Jane
Mondou, Elsa
Quinn, Joe
Rousseau, Franck
HEPATOLOGY, 2008, 48 (04) : 376A - 376A
[26] Improved bone and renal safety of switching from tenofovir disoproxil fumarate to tenofovir alafenamide: preliminary results from 2 phase 3 studies in HBeAg-positive and HBeAg-negative patients with chronic hepatitis B
Chan, H. L.
Fung, S.
Seto, W. K.
Gane, E.
Flaherty, J. F.
Suri, V.
Lin, L.
Gaggar, A.
Subramanian, G. M.
Chuang, W. L.
Agarwal, K.
Janssen, H. L.
Buti, M.
JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S25 - S25
[27] IS HBEAG LOSS ASSOCIATED WITH AN IMPROVED OUTCOME IN HEPATITIS B PATIENTS TREATED WITH TENOFOVIR DISOPROXIL FUMARATE (TDF)?
Fung, S.
Buti, M.
Gane, E.
Afdhal, N.
Flaherty, J.
Martins, E.
Bekele, N.
Bornstein, J.
Marcellin, P.
JOURNAL OF HEPATOLOGY, 2012, 56 : S200 - S200
[28] EFFICACY AND SAFETY RESULTS 48 WEEKS AFTER SWITCHING FROM TENOFOVIR DISOPROXIL FUMARATE (TDF) TO TENOFOVIR ALAFENAMIDE (TAF) VS CONTINUED TDF TREATMENT IN VIROLOGICALLY-SUPPRESSED PATIENTS WITH CHRONIC HEPATITIS B (CHB)
Lampertico, Pietro
Buti, Maria
Fung, Scott
Ahn, Sang Hoon
Chuang, Wan-Long
Tak, Won Young
Ramji, Alnoor
Chen, Chi-Yi
Tam, Edward
Bae, Ho
Ma, Xiaoli
Flaherty, John F.
Gaggar, Anuj
Lau, Audrey H.
Feierbach, Becket
Wu, George
Suri, Vithika
Subramanian, Mani
Trinh, Huy N.
Yoon, Seung-Kew
Agarwal, Kosh
Lim, Young-Suk
Chan, Henry L.
GASTROENTEROLOGY, 2019, 156 (06) : S1195 - S1195
[29] A phase 3 study comparing tenofovir alafenamide (TAF) to tenofovir disoproxil fumarate (TDF) in patients with HBeAg-positive, chronic hepatitis B (CHB): efficacy and safety results at week 96
Agarwal, K.
Fung, S.
Seto, W. K.
Lim, Y. S.
Gane, E.
Janssen, H. L.
Sharma, M.
Chuang, W. L.
Bae, H.
Yoon, K. T.
Flaherty, J. F.
Lau, A.
Gaggar, A.
Suri, V.
Cathcart, A.
Lin, L.
Subramanian, G. M.
Shalimar
Furusyo, N.
Buti, M.
Chan, H. L.
JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S478 - S478
[30] Efficacy and Safety of Tenofovir Disoproxil Fumarate in Treatment-Naive Patients with Chronic Hepatitis B in Korea
Kwon, Jung Hyun
Song, Myeong Jun
Jang, Jeong Won
Bae, Si Hyun
Choi, Jong Young
Yoon, Seung Kew
Kim, Hee Yeon
Kim, Chang Wook
Song, Do Seon
Chang, U. Im
Yang, Jin Mo
You, Chan Ran
Choi, Sang Wook
Lee, Hae Lim
Lee, Sung Won
Han, Nam Ik
Nam, Soon Woo
Kim, Sang Gyune
Kim, Young Seok
Kim, Seok Hyun
Lee, Byung Seok
Lee, Tae Hee
Cho, Eun-Young
DIGESTIVE DISEASES AND SCIENCES, 2019, 64 (07) : 2039 - 2048

← 1 2 3 4 5 →